Freenome’s multiomics platform is being used in a Phase II clinical trial to help identify patients most likely to respond to ADC Therapeutics’ antibody drug conjugate.
Freenome is working with a CRO as part of a clinical trial evaluating the company’s multi-omics blood testing platform – which the CEO says helps de-risk drug development by characterizing likely responders to therapy, among other use cases.